# QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT01670994** · PHASE1,PHASE2 · TERMINATED · sponsor: **Altor BioScience** · enrollment: 6 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ALT-801

## Key facts

- **NCT ID:** NCT01670994
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-14
- **Primary completion:** 2015-09-09
- **Final completion:** 2015-09-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Patient population did not benefit from single agent treatment.
- **Last updated:** 2024-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670994, "QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01670994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*